8800 Health Science Center Parkway
Bryan, TX 77807-1107
United States
302 355 0650
https://www.ibioinc.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 26
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Dr. Martin B. Brenner D.V.M., Ph.D. | CEO & Chief Scientific Officer | 577.31k | N/D | 1971 |
Mr. Felipe Duran | Chief Financial Officer | 1.07M | N/D | 1980 |
Stephen Kilmer | Investor Relations Officer | N/D | N/D | N/D |
Mr. Marc Banjak J.D. | General Counsel | N/D | N/D | N/D |
Mr. Robert B. Kay | Interim Secretary & Interim Treasurer | 92.69k | N/D | 1940 |
iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.
La calificación ISS Governance QuickScore de iBio, Inc. a partir del 1 de marzo de 2024 es 8. Las puntuaciones principales son Auditoría: 10; Junta: 6; Derechos del accionista: 4; Compensación: 9.